Evolus, Inc. commercializes cash-pay medical aesthetic products for the global performance beauty market. Its portfolio centers on Jeuveau® (prabotulinumtoxinA-xvfs), known as Nuceiva® outside the United States, and injectable hyaluronic acid gel collections marketed under the Evolysse® and Estyme® brands.
Recurring Evolus news includes quarterly financial results, revenue outlooks, product and market expansion for injectable aesthetics, CE Mark certification for HA gel collections, national-account and customer engagement updates, healthcare conference participation, and equity compensation grants under Nasdaq inducement rules. Company updates also discuss operations across the United States, Canada, Europe, and Australia.
Evolus (NASDAQ: EOLS) reported Q1 2026 net revenue $73.1M, up 7% year-over-year, with GAAP operating loss $6.8M and Adjusted EBITDA $0.6M (second consecutive quarter positive). The company reaffirmed 2026 guidance of $327M–$337M revenue and $210M–$216M non-GAAP operating expenses, and noted cash of $49.8M. Key commercial milestones include an Estyme Europe launch in mid-May and anticipated U.S. approval of Evolysse Sculpt in Q4 2026.
Evolus (NASDAQ: EOLS) will report its first quarter 2026 financial results on Monday, May 4, 2026, after U.S. markets close. Management will host a conference call and live webcast the same day at 4:30 p.m. ET, followed by a Q&A session.
Dial-in numbers, a telephonic replay and an archived webcast will be available via the company's Investor Relations page.
Evolus (NASDAQ: EOLS) said members of its management team will join a fireside chat and investor meetings at the Needham 25th Annual Virtual Healthcare Conference on April 14, 2026 at 3:45 PM ET.
According to Evolus, the live webcast is accessible on the company Investor Relations page and a replay will be available for 90 days after the presentation.
Evolus (NASDAQ: EOLS) reported inducement grants made in March 2026 under its 2023 Inducement Incentive Plan. The company granted an aggregate of 85,516 RSUs and 8,635 stock options to 10 newly hired non-executive employees, approved by the compensation committee.
The awards vest 25% on each annual anniversary beginning at the vesting commencement date. Options’ exercise price equals the closing price on the last business day prior to each grant. Awards are subject to plan and grant agreement terms, including continuous employment requirements on vesting dates.
Evolus (NASDAQ: EOLS) reported Q4 2025 revenue of $90.3M and full‑year 2025 revenue of $297.2M, representing 14% and 12% growth respectively, its sixth consecutive year of double‑digit growth. The company achieved GAAP operating income of $4.2M in Q4 and ended 2025 with $53.8M cash.
Management provided 2026 guidance of $327M–$337M revenue (10%–13% growth), non‑GAAP operating expense of $210M–$216M (0%–3% growth), and expects a low‑ to mid‑single digit adjusted EBITDA margin in 2026, while forecasting $450M–$500M revenue and 13%–15% adjusted EBITDA margins in 2028.
Evolus (NASDAQ: EOLS) said its management team will participate in a fireside chat and investor meetings at the Leerink Partners Global Healthcare Conference in Miami on Wednesday, March 11, 2026 at 11:20 AM ET. The webcast will be available on the company Investor Relations page and a replay will be posted for 90 days.
Evolus (NASDAQ: EOLS) will report fourth quarter and full-year 2025 financial results on Tuesday, March 3, 2026 after U.S. market close. Management will host a conference call and live webcast at 4:30 p.m. ET the same day, followed by Q&A.
Dial-in numbers, webcast links, telephonic replay details, and an archived webcast will be available on the company's Investor Relations website.
Evolus (NASDAQ: EOLS) announced inducement equity grants to 36 newly hired non-executive employees comprising 153,218 restricted stock units and 34,952 stock options granted between December 7, 2025 and February 7, 2026.
The awards were approved under the 2023 Inducement Incentive Plan, vest 25% annually, and options carry an exercise price equal to the closing price on the last business day before each grant date.
Evolus (NASDAQ: EOLS) reported preliminary unaudited net revenue of $88.6M–$90.6M for Q4 2025 (up 12%–15% YoY) and $295.5M–$297.5M for full-year 2025 (up 11%–12% YoY). The company reaffirmed Q4 2025 non-GAAP operating income of $5M–$7M and provided 2026 net revenue guidance of $327M–$337M (11%–13% growth vs. preliminary 2025). Evolysse and Estyme injectable HA gels are expected to contribute 10%–12% of 2026 revenue. Cash and equivalents were $53M as of Dec 31, 2025. Long-term outlook updated to $450M–$500M revenue for 2028 with 13%–15% non-GAAP operating margins.
Evolus (NASDAQ: EOLS) announced inducement equity grants approved under the Evolus 2023 Inducement Incentive Plan with a grant and vesting commencement date of November 7, 2025.
The company granted non-qualified stock options to purchase an aggregate of 17,871 shares and 45,063 restricted stock units (RSUs) to 13 newly hired non-executive employees. The stock options carry an exercise price of $6.56 (closing price on November 7, 2025), a 10-year term, and vest over 4 years with 25% vesting each annual anniversary. RSUs vest 25% on each annual anniversary.
All awards are subject to the plan and to individual award agreements, including continuous employment vesting conditions, and were approved as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).